FDA keeps brand-name drugs on a fast path to market, despite manufacturing concerns
from San Francisco Chronicle
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they’d accomplished. "I voted 'yes' because, quite simply, this is a game-changer," National Institutes of Health hepatologist Dr. Marc Ghany said of Sovaldi, Gilead Sciences' new pill designed to cure most cases of hepatitis C within 12 weeks.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063